References
- Wang Y , QiuT, ZhouJ, FrancoisC, ToumiM. Which criteria are considered and how are they evaluated in health technology assessments? A review of methodological guidelines used in Western and Asian Countries. Appl. Health Econ. Health Policy19(3), 281–304 (2021).
- Hariton E , LocascioJJ. Randomised controlled trials – the gold standard for effectiveness research. BJOG Int. J. Obstet. Gynaecol.125(13), 1716 (2018).
- World Cancer Research Fund (WCRF) . Worldwide cancer data (2022). www.wcrf.org/cancer-trends/worldwide-cancer-data/
- International Agency for Research on Cancer (IARC) . Cancer today (2022). http://gco.iarc.fr/today/home
- Global Burden of Disease Cancer Collaboration . Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol.4(11), 1553–1568 (2018).
- Gyawali B , HeySP, KesselheimAS. Assessment of the clinical benefit of cancer drugs receiving accelerated approval. JAMA Intern. Med.179(7), 906–913 (2019).
- Garrison LP , NeumanPJ, EricksonP, MarshallD, MullinsCD. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health J. Int. Soc. Pharmacoeconomics Outcomes Res.10(5), 326–335 (2007).
- Makady A , HamRT, DeBoer Aet al. Policies for use of real-world data in health technology assessment (HTA): a comparative study of six HTA agencies. Value Health20(4), 520–532 (2017).
- NICE . NICE real-world evidence framework (2022). www.nice.org.uk/corporate/ecd9/chapter/overview
- HAS . Real-world studies for the assessment of medicinal products and medical devices (2021). www.has-sante.fr/upload/docs/application/pdf/2021-06/real-world_studies_for_the_assessment_of_medicinal_products_and_medical_devices.pdf
- IQWiG . General Methods Version 6.1 (2022). www.iqwig.de/methoden/general-methods_version-6-1.pdf
- CADTH . Use of Real-World Evidence in Single-Drug Assessments (2018). www.cadth.ca/sites/default/files/pdf/es0323-rwe-in-single-drug-appraisal.pdf
- Sherman RE , AndersonSA, DalPan GJ, Et Al. Real-world evidence What is it and what can it tell us?N. Engl. J. Med.375(23), 2293–2297 (2016).
- Government of Canada . Optimizing the use of real world evidence to inform regulatory decision-making (2019). www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/announcements/optimizing-real-world-evidence-regulatory-decisions.html
- Makady A , Van VeelenA, JonssonPet al. Using real-world data in health technology assessment (HTA) practice: a comparative study of five HTA agencies. Pharmacoeconomics36, 359–368 (2018).
- Lou J , SarinKC, TohKYet al. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward. J. Technol. Assess. Health Care36, 474–480 (2020).
- Bullement A , PodkonjakT, RobinsonMJet al. Real-world evidence use in assessments of cancer drugs by NICE. Int. J. Technol. Assess. Health Care36, 388–394 (2020).
- Real-World Evidence (2022). https://www.ispor.org/strategic-initiatives/real-world-evidence
- Klonoff C . The new FDA real-world evidence program to support development of drugs and biologics. J. Diabetes Sci. Technol.14, 345–349 (2019).
- Bell H , WailooAJ, HernandezMet al. The use of real world data for the estimation of treatment effects in NICE decision making. Decision Support Unit (2016). www.sheffield.ac.uk/sites/default/files/2022-02/RWD-DSU-REPORT-Updated-DECEMBER-2016.pdf
- Crump M , NeelapuSS, FarooqUet al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood130(16), 1800–1808 (2017).
- CADTH . Optimal use report. Tisagenlecleucel for diffuse large B-cell lymphoma: Economic review report.8(3e), 1–68 (2019).
- Scottish Medicines Consortium . Tisagenlecleucel (Kymriah) (2021). www.scottishmedicines.org.uk/medicines-advice/tisagenlecleucel-kymriah-resubmission-smc2200/
- INESSS . AVIS sur le tisagenlecleucel pour le traitement du lymphome diffus à grandes cellules B récidivant ou réfractaire (2019). https://numerique.banq.qc.ca/patrimoine/details/52327/3582882
- IQWiG . [G18-10] Tisagenlecleucel (diffuse large B-cell lymphoma) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V (2018). www.iqwig.de/en/projects/g18-10.html
- NICE . Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies (2018). www.nice.org.uk/guidance/ta559
- HAS . KYMRIAH (tisagenlecleucel), CAR T anti-CD19 (LDGCB) (2019). www.has-sante.fr/jcms/c_2891692/fr/kymriah-tisagenlecleucel-car-t-anti-cd19-ldgcb
- IQWiG . [A17-40] Daratumumab (multiple myeloma) – Benefit assessment according to §35a Social Code Book V (2017). www.iqwig.de/download/a17-40_daratumumab_extract-of-dossier-assessment_v1-0.pdf
- NICE . Daratumumab monotherapy for treating relapsed and refractory multiple myeloma. Technical appraisal guidance [TA150] (2018). www.nice.org.uk/guidance/ta510
- Scottish Medicines Consortium . daratumumab (Darzalex) (2017). www.scottishmedicines.org.uk/media/1521/daratumumab_darzalex_resubmission_final_sept_2017_for_website.pdf
- HAS . DARZALEX (daratumumab), anticorps monoclonal - monothérapie (2019). www.has-sante.fr/jcms/c_2808595/fr/darzalex-daratumumab-anticorps-monoclonal-monotherapie
- INESSS DARZALEX. https://www.inesss.qc.ca/thematiques/medicaments/medicaments-evaluation-aux-fins-dinscription/extrait-davis-au-ministre/darzalex-5616.html?DemandePluginController%5Bonglet%5D=0&cHash=00ffdd9fa17d8655f8ba588589587dc1
- CADTH . Darzalex for multiple myeloma – details (2016). www.cadth.ca/darzalex-multiple-myeloma-details
- Cook G , CorsoA, StreetlyMet al. Daratumumab monotherapy for relapsed or refractory multiple myeloma: results of an early access treatment protocol in Europe and Russia. Oncol. Ther. (1), 139–151 (2021).
- IQWiG . General methods 4.2. (2020). www.iqwig.de/methoden/iqwig_general_methods_version_204-2.pdf
- NICE . Increasing use of health and social care data in guidance development. www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-guidelines/how-we-develop-nice-guidelines/data-and-analytics-statement-of-intent